Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:
Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
July 1 is the anniversary of the founding of the Communist Party of China. The party committee of the group organized the party members of the group headquarters and the heads of the grassroots party organizations to go to Jinggangshan, the red holy land, to retake the revolutionary road taken by the ancestors and review the history of revolutionary struggle.
2023
07-11
The Party Committee of the Group organized a thematic education seminar to study
On June 27, the Party Committee of the Group Company organized an education seminar on the theme of studying and implementing Xi Jinping's thoughts on socialism with Chinese characteristics in the new era. Jiang Xinwang, a professor and master tutor of Zhejiang Normal University, explained the deployment requirements of economic work and Xi Jinping's economic thoughts in the report of the 20th National Congress of the Communist Party of China with the theme of "accelerating the construction of a new development pattern and promoting high-quality development.
2023
07-11
Jianfeng Pharmaceutical rehired Academician Wang Guangji as Chief Scientist
On April 30, Jiang Xiaomeng, chairman of the group company and chairman of Jianfeng Pharmaceutical Company, on behalf of Jianfeng Pharmaceutical Company, issued a letter of appointment to Professor Wang Guangji, academician of the Chinese Academy of Engineering, and renewed him as the chief scientist of the pharmaceutical company.
2023
05-11
Jinhua Development Conference and Wucheng Development Conference
On April 30 and May 1, the third Jinhua Development Conference and the second Wucheng Development Conference opened successively. Jiang Xiaomeng, secretary of the party committee and chairman of the group company, won two major awards at the "Jinhua Development Outstanding Achievement Award" and "Wucheng Development Merit Award" at the two conferences, and participated in the Jinhua Life and Health Industry Summit roundtable and other activities.
2023
05-11
Daye Peak Cement Company, National "Green Factory"!
The Ministry of Industry and Information Technology recently announced the 2022 national green manufacturing list, Daye Peak Cement Company successfully ranked among the national "green factories. Green manufacturing is also known as environmentally conscious manufacturing, that is, in the manufacturing process, a modern manufacturing model that comprehensively considers environmental impact and resource benefits. Its purpose is to use technical means to optimize manufacturing procedures, minimize the impact on the environment (negative effect), and resource utilization The highest rate, and the coordination and optimization of economic and social benefits of enterprises, so as to achieve the purpose of resource conservation and sustainable development. In recent years, with the rapid development of social economy, the state attaches great importance to the construction of ecological civilization and ecological environment protection, and further promoting the construction of green manufacturing system has become an important means to promote high-quality development and maintain green water and green mountains forever. As an important part of the green manufacturing system, the Ministry of Industry and Information Technology has organized and carried out the creation of national-level green factories since 2017, and has conducted nationwide selection. It is an authoritative recognition for companies that meet the "green development" and aims to improve my country's green Manufacturing system, comprehensive implementation of green manufacturing, and help the industrial sector achieve the goal of carbon peak and carbon neutrality, it is an important way to promote the structural optimization of various industries, to get out of trouble and upgrade, and to improve quality and efficiency. Green factory refers to the realization of land intensive, raw materials harmless, clean production, waste resources, energy low-carbon factories. As the production unit of the manufacturing industry, the factory is the main body of the implementation of green manufacturing, which belongs to the core support unit of the green manufacturing system, focusing on the greening of the production process. Over the years, Daye Jianfeng has been adhering to the concept of green and low-carbon development, making every effort to build a garden-style factory. Through formulating plans and subdividing targets, it has clearly defined the total energy consumption and pollutant emission targets, and through carrying out school-enterprise cooperation to promote industry-university-research, it has actively implemented the strategy of "carbon peak and carbon neutrality", invested a huge amount of funds every year for technological transformation, and successively implemented technological transformation projects such as electric bags and low-nitrogen combustion upgrading, take the lead in the application of emission reduction technologies such as wet desulfurization and precise denitrification in the cement industry in Hubei Province, and continue to promote energy conservation, consumption reduction, and emission reduction. After the technical transformation, the company can save 3000 tons of standard coal every year, reduce the intensity of carbon dioxide emissions by 3.6, improve the level of energy-saving and green environmental protection management, and achieve the goal of creating a green factory. Being rated as a national-level green factory is not only a high affirmation and encouragement of Daye Peak's adherence to green, low-carbon and innovative development, but also an opportunity for Daye Peak to further promote green development. The person in charge of Daye Peak said that in accordance with national requirements, local industrial and information authorities should strengthen the connection between the units listed in the green manufacturing list and relevant industrial policies, give full play to the demonstration role of point to area, lead the green transformation of the manufacturing industry in the region, strengthen tracking guidance and dynamic management, and review the key indicators specified in the dynamic management table, Daye Peak will be in the future work, we will continue to further promote the management of environmental protection, energy conservation and emission reduction, give full play to the leading role of green factories in benchmarking, make low-carbon energy conservation, green environmental protection and reduce energy consumption the main keynote of enterprise development, and make continuous efforts to promote the high-quality development of enterprises and local economy. (Junin)
2023
04-03
"Cement Economy 50 People Forum" Jiang Xiaomeng Talk about the Future Development of Cement Industry
On March 14, the "Cement Economy 50 Forum" hosted by China Cement Network was held in Hangzhou, inviting 50 influential economic figures in the cement industry to discuss the future development of China's cement industry. Jiang Xiaomeng, chairman of the group company, was invited to attend the forum to discuss the development of the cement industry with his peers. The theme of this forum is "strengthening confidence, seeking breakthrough, and promoting development". It aims to point out the disadvantages of "mud", actively provide suggestions for the competent departments, enterprise transformation and upgrading, strategic and tactical decision-making in the difficult period of the cement industry, and provide new think tank opinions and methods to help form a new cement economic ecology. In the context of the sharp decline in demand, the cement industry is trapped inside and outside, how to revive the glory? How do cement companies survive and develop next? Around these two topics, the guests at the meeting had a heated discussion. Jiang Xiaomeng pointed out in his speech at the forum that the development of any enterprise is inseparable from the healthy development of the industry. Only when the industry is good can the enterprise be good, and the interests of the industry are greater than the interests of the enterprise. In addition, the competition of similar enterprises should seek a breakthrough from the differentiation, and it is unreasonable to blindly pursue low prices. Industry synergy, industry synergy, supply, demand, price, to find a common price line, on the basis of competition and cooperation, from the management services, cost control and other aspects to highlight the advantages of enterprises. The participants reached consensus on many issues after heated discussions. It is generally believed that 2022 is the most complex year in the cement industry in the past decade, affected by the multi-point spread of the epidemic, real estate downturn and other factors, the cement market demand is sluggish, the contradiction between supply and demand is prominent, prices are falling rapidly, business difficulties, the pace of steady growth of the industry is blocked. Entering 2023, under the macroeconomic situation of stabilizing the economy and promoting development, as well as various regions stepping up efforts to promote the construction of major projects, cement demand is expected to increase in 2023 compared with 2022, and the situation in the second half of the year will be better than that in the first half. However, under the expectation of restorative growth in demand, the cement industry is still facing uncertainties such as continued bottoming of real estate, high energy costs, and overcapacity. In this regard, we should resolutely maintain the normal order of the industry, make concerted efforts to help the industry get out of the predicament, and firmly implement staggered peak production. Through mergers and acquisitions, carbon quotas, energy efficiency indicators, environmental protection indicators, coal indicators, market competition and other means to further resolve the contradiction of overcapacity, optimize the industrial layout, and adhere to innovation-driven in digital, intelligent and green development, so as to promote and finally realize the high-quality development of the cement industry. (this newspaper reporter)
2023
03-21
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page